Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Nicholas Whipple et al.|Neuro-Oncology|2022Cited by 136
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J. Church, Katherine A. Janeway, Laura Corson et al.|Nature Medicine|2022Cited by 65
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61